Cargando...
Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has failed in many ways to be as potent in the anti-cancer role as pre-clinical studies would have suggested. This paper traces some aspects of this failure to a compensatory erlotinib-mediated increase in interleuk...
Gardado en:
| Publicado en: | Springerplus |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4628020/ https://ncbi.nlm.nih.gov/pubmed/26543772 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-015-1441-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|